Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer
Under a Creative Commons license
open access
Keywords
Pharmacoeconomics
Cost-effectiveness analysis
Non-small cell lung cancer
Gefitinib
Individualized medicine
Cited by (0)
Copyright © 2015 The Authors. Published by Elsevier Ireland Ltd.